Skip to main content

Table 5 Disease-free survival or recurrence-free survival among patients with colorectal cancer according to CIMP status

From: Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review

CIMP definition First author (year) Subgroup Subgroup size Analysis Survival HR (95 % CI) Comparison group p value Covariates adjusted for
CIMP+/ CIMP-H CIMP-L
CRC patients          
 D 2 Kalady (2009) [17] All 357 M RFS 2.08 (0.65–6.65)a   CIMP− 0.21 Age, sex, stage, MSIb
 D 9 Hokazono (2014) [33] All 104 M RFS 0.29 (0.02–1.42)   CIMP− 0.15 Not report
CRC patients by cancer stages          
 D 9 Hokazono (2014) [33] I–II 50 M RFS 0.01 (0.00–2.28)   CIMP−   Not report
 D 1 Ju (2011) [38] I–III 53 M RFS 1.05 (0.33–3.39)   CIMP− 0.93 Age, sex, stage
 D 2 Min (2011) [25] I–III 124 M RFS 0.81 (0.21–3.14)   CIMP−   Age, sex, stage, BRAF, KRAS, MGMTb
 D 6 Ward (2003) [37] I–III 476 U RFS 0.90 (0.50–2.00)   CIMP− 0.94 No
 D 8 Jover (2011) [5] II–III 196 M DFS 1.20 (0.80–2.00)   CIMP− 0.40 Age, stage, adjuvant chemotherapy
 D 10 Wang (2014) [36] II–III 50 M DFS 2.94 (1.19–7.22)   CIMP− 0.02 Stage, location
 D 2 Donada (2013) [40] II, colon 120 M DFS 0.58   CIMP− 0.20 All variablesc
 D 9 Hokazono (2014) [33] III 39 M RFS 0.45 (0.01–2.23)   CIMP−   Not report
CRC patients by location of CRC          
 D 3 Bae (2013) [28] Proximal 165 M DFS 1.00 (0.53–1.88)   CIMP− 0.99 Stagec
 D 3 Bae (2013) [28] Distal 327 M DFS 1.31 (0.51–3.36)   CIMP− 0.58 Stagec
 D 2 Donada (2013) [40] Colon, II 120 M DFS 0.58   CIMP− 0.20 All variablesc
 D 1 Samowitz (2009) [20] Rectal 990 M DFS 1.32 (0.88–1.97)   CIMP−   Age, stage, BRAF, MSI, KRAS, TP53d
 D 3 Bae (2013) [28] Rectal 242 M DFS 2.90 (1.04–8.08)   CIMP− 0.04 Stagec
CRC patients by microsatellite instability         
 D 3 Kim (2013) [29] MSI 220 M DFS 2.25 (1.11–4.57)   CIMP− 0.03 Age, stage, differentiation, BRAFe
  1. CI confidence interval, DFS disease-free survival, HR hazard ratio, M multivariate analysis, RFS recurrence-free survival, U univariate analysis
  2. aThe original data of HR (95 % CI) was 0.48 (0.15–1.53) derived from CIMP− compared with CIMP+
  3. bOther covariates included in the multivariate analysis are: differentiation, chemotherapy
  4. cOriginal paper mentioned the multivariate analysis including all clinical, pathological and molecular variables
  5. dMultivariate analysis adjusted BRAF, MSI, KRAS, and TP53, in addition to age and stage, the result adjusted for only age and stage was 1.45 (1.02–2.07)
  6. eOther covariates included in the multivariate analysis are Crohn’s-like lymphoid reaction and peritumoral lymphocytic reaction